This event is not part of the official Internal Medicine Meeting 2025 Education Program. CME credit is provided by organizations other than ACP.
Thursday, April 03, 2025
6:00 PM – 6:30 PM CT Registration & Dinner
6:30 PM – 7:30 PM CT CE Symposium
Hilton New Orleans Riverside
2 Poydras Street
New Orleans, LA
Meeting Location: St. James Ballroom
PROGRAM FEATURES
-
- Downloadable animations
- Interactive, case-based learning environment
- Create-your-own personalized poster
PRESENTING FACULTY
 |
Marc Agronin, MD Chief Medical Officer Frank C. and Lynn Scaduto MIND Institute and Behavioral Health Miami Jewish Health Miami, FL |
 |
Natalie Christian, MD Assistant Professor, Geriatrics Program Director, Geriatric Medicine Fellowship Tulane University School of Medicine Southeast Louisiana Veterans Healthcare System New Orleans, LA |
PROGRAM OVERVIEW
The goal of this program is to provide practicing clinicians recommendations informing the use of disease-modifying therapies (DMTs) for Alzheimer’s disease (AD) and the identification of those who qualify for treatment based on available clinical data, as well as information on how to manage potential adverse events associated with DMTs for AD using a multidisciplinary approach.
TARGET AUDIENCE
This activity is designed to meet the educational needs of healthcare providers involved in the diagnosis and continued care of patients with Alzheimer’s disease, including primary care physicians, neurologists, geriatricians, psychiatrists, nurses, nurse practitioners, physician assistants, and other multidisciplinary team members.
LEARNING OBJECTIVES
Upon completion of this program, attendees should be able to:
- Integrate evidence-based pathways for screening, diagnosing, and staging MCI and AD
- Appraise clinical practice recommendations informing use of DMTs for AD and identifying those who qualify for treatment based on available clinical data
- Assess and manage potential adverse events associated with DMTs for AD using a multidisciplinary approach
- Develop practice protocols to improve access to DMTs for AD
- Apply best practices for shared decision making when discussing DMT treatment for AD, including discussions of treatment benefits, risks, and what to expect with therapy. Evaluate the efficacy, safety, and tolerability findings from studies on novel BP treatment options that target different immune pathways
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event Staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to the live event at [email protected]
